<SEC-DOCUMENT>0001193125-16-657175.txt : 20160726
<SEC-HEADER>0001193125-16-657175.hdr.sgml : 20160726
<ACCEPTANCE-DATETIME>20160726060839
ACCESSION NUMBER:		0001193125-16-657175
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20160725
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160726
DATE AS OF CHANGE:		20160726

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FIBROGEN INC
		CENTRAL INDEX KEY:			0000921299
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36740
		FILM NUMBER:		161783054

	BUSINESS ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		415-978-1200

	MAIL ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d212886d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): July&nbsp;25, 2016 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>FibroGen, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-36740</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>77-0357827</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FibroGen, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>409 Illinois Street </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>San
Francisco, CA 94158 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(415) 978-1200 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
name or former address, if changed since last report.) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Events </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;25, 2016, FibroGen, Inc. issued a press release with its
collaboration partner Astellas Pharma Inc. confirming the initiation of their Phase 3 studies of roxadustat in patients with chronic kidney disease (&#147;CKD&#148;) in Japan and announcing results from their two completed Phase 2 studies of
roxadustat in patients with CKD in Japan. A copy of such press release is furnished as Exhibit&nbsp;99.1 to this report and is incorporated herein by reference. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Exhibits </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B></B>Description<B></B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release titled &#147;Astellas and FibroGen Announce First Patient Treated in Phase 3 Studies and Positive Phase 2 Results of Roxadustat in Patients with Chronic Kidney Disease in Japan&#148; dated July 25, 2016</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>FIBROGEN, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: July 26, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Lowenstein</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Michael Lowenstein</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Legal Counsel</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEX TO EXHIBITS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B></B>Description<B></B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release titled &#147;Astellas and FibroGen Announce First Patient Treated in Phase 3 Studies and Positive Phase 2 Results of Roxadustat in Patients with Chronic Kidney Disease in Japan&#148; dated July 25, 2016</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d212886dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">


<IMG SRC="g212886img1.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g212886img2.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Astellas and FibroGen Announce First Patient Treated in Phase 3 Studies and Positive </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Phase 2 Results of Roxadustat in Patients with Chronic Kidney Disease in Japan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tokyo and San Francisco, July&nbsp;25, 2016</I></B> &#151; Astellas Pharma Inc. (TSE:4503, &#147;Astellas&#148;) and FibroGen, Inc. (Nasdaq: FGEN)
(&#147;FibroGen&#148;), today announced the dosing of the first patient in Phase 3 trials in Japan of roxadustat (development code: ASP1517/FG-4592) for treatment of anemia in chronic kidney disease (CKD), which triggered a $10 million milestone
payment from Astellas to FibroGen. The initiation of Phase 3 studies in Japan follows the positive results from two Phase 2 studies in Japan of roxadustat in CKD patients on dialysis and in CKD patients not on dialysis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the Phase 2 studies in Japan of CKD patients receiving dialysis and not receiving dialysis, roxadustat was well tolerated and met the primary objective of
demonstrating dose-related rates of hemoglobin (Hb) increase measured over the first six weeks of treatment, as well as anemia correction and Hb maintenance over the 24-week treatment period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Anemia is a common consequence of CKD and contributes to the poor quality of life associated with this disease,&#148; said Dr.&nbsp;Bernie Zeiher,
President, Development of Astellas. &#147;We are pleased to advance roxadustat to Phase 3 studies in Japan, as a potential new oral treatment of anemia in CKD patients.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are encouraged by accumulated results showing roxadustat&#146;s potential to be effective in treating anemia and well tolerated in Phase 2 clinical
studies around the globe in multiple types of CKD patients with anemia. We appreciate the strong support from patients and physicians with respect to the roxadustat clinical development program, and believe roxadustat has the potential to improve
the care of CKD patients with anemia,&#148; said Thomas B. Neff, Chief Executive Officer of FibroGen. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the Studies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Phase 2 study in Japan of CKD patients not on dialysis was a multi-center, randomized, parallel-group, placebo-controlled, double-blind study over 24
weeks. The subjects, 107 CKD patients not yet receiving dialysis, were randomized to one of three roxadustat treatment arms (50 mg, 70 mg, 100 mg) or to a placebo arm, with roxadustat orally administered three times weekly (TIW) for the first six
weeks of the study to evaluate dose response of efficacy and safety. This was followed by dose titration every four weeks until hemoglobin response was achieved, at which point hemoglobin was maintained with patients randomized to one of two dosing
regimens (continuation of TIW dosing or a change to weekly (QW) dosing). </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Results showed achievement in the full analysis set of dose response in the three roxadustat treatment arms, with
a mean rate of Hb increase of 0.200, 0.453, and 0.570 g/dL per week (50 mg, 70 mg, 100 mg, respectively), as measured over the first six weeks of the study, compared to a mean Hb decrease of 0.052 g/dL per week in subjects receiving placebo. Of
note, 93.8% of roxadustat-treated subjects achieved hemoglobin correction as measured by hemoglobin response defined as Hb more than or equal to 10 g/dL and Hb increase of at least 1 g/dL from baseline. In the placebo arm, hemoglobin response was
achieved in 14.8% of the subjects. Roxadustat was well tolerated, with no deaths and no major adverse cardiovascular events reported for roxadustat-treated patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Phase 2 study in Japan in 130 CKD patients receiving dialysis was a multi-center, randomized, darbepoetin-controlled, double blind (roxadustat arms),
open-label (darbepoetin) study over 24 weeks in CKD patients on chronic stable dialysis. The subjects who had discontinued previous standard-of-care therapy (erythropoiesis-stimulating agents) to reach Hb levels of &lt; 9.5 g/dL were randomized to
one of three roxadustat arms (administered orally TIW at a fixed dose) or to the darbepoetin arm (darbepoetin administered intravenously QW) over the first six weeks of the study to evaluate dose response of efficacy and safety, followed by dose
titration to the desired Hb level every four weeks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During weeks 18 to 24, average Hb levels achieved (a secondary endpoint) in the full analysis set
were 10.31 g/dL (1.33 g/dL Hb increase), 10.20 g/dL (1.37 g/dL Hb increase), and 10.53 g/dL (1.57 g/dL Hb increase), respectively, in the roxadustat treatment arms, compared to 10.25 g/dL (1.42 g/dL Hb increase) in the darbepoetin arm. Roxadustat
was well tolerated in this study, with one death reported in a subject who suffered from bacterial pneumonia and thromboembolism, whose death was deemed unrelated to roxadustat; no deaths were reported in the other treatment arms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FibroGen and development partner Astellas have, in total, completed six roxadustat Phase 2 studies in CKD patients on dialysis and CKD patients not on
dialysis in the U.S., Europe and China. The results reported in these Phase 2 studies in Japan are consistent with the results from the Phase 2 studies in other regions. Completion of these studies enabled Astellas to initiate the Phase 3 clinical
development program in Japan in 2016. This is consistent with the ongoing Phase 3 clinical development program for roxadustat and treatment of anemia in CKD patients that includes 10 current Phase 3 studies: eight global studies in support of U.S.
and Europe requirements and two studies in support of China marketing approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About roxadustat </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roxadustat is currently in Phase 3 development as a potential therapy for anemia associated with CKD in both patients on dialysis and not on dialysis.
Roxadustat is an orally administered small molecule inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase activity. HIF is a protein transcription factor that induces the natural physiological response to conditions of low oxygen,
&#147;turning on&#148; erythropoiesis (the process by which red blood cells are produced) and other protective pathways. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Astellas and FibroGen are collaborating on the development and commercialization of roxadustat for the treatment
of anemia in patients with CKD in territories including Japan, Europe, the Commonwealth of Independent States, the Middle East and South Africa. AstraZeneca and FibroGen are collaborating on the development and commercialization of roxadustat for
the treatment of anemia in patients with CKD in the U.S., China, and other markets. For information about roxadustat studies that are currently recruiting patients, please visit clinicaltrials.gov at this link: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>https://clinicaltrials.gov/ct2/results?term=roxadustat&amp;Search=Search</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Chronic Kidney Disease </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chronic kidney disease
(CKD) affects more than 200&nbsp;million people worldwide and more than 30&nbsp;million adults in the U.S. Although it can occur at any age, it becomes more common in aging populations, and the prevalence is increasing. Anemia is a common
complication of CKD and is associated with significant morbidity and mortality in dialysis and non-dialysis populations. In addition, CKD can be both a cause and a consequence of cardiovascular disease and is now a critical worldwide healthcare
issue that represents a large and growing unmet medical need. Currently, no curative treatment or ability to stop kidney deterioration in patients with CKD exists with the exception of kidney transplantation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Astellas </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Astellas Pharma Inc., based in Tokyo,
Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized
therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business.
Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About FibroGen </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FibroGen is a research-based
biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. The company utilizes its extensive experience in fibrosis and hypoxia-inducible factor (HIF) biology to
generate development programs in multiple therapeutic areas. Its most advanced product candidate, roxadustat, or FG-4592, is an oral small molecule inhibitor of HIF prolyl hydroxylases, or HIF-PHs, in Phase 3 clinical development for the treatment
of anemia in CKD. A second product candidate, FG-3019, is a monoclonal antibody in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, and Duchenne muscular dystrophy. For more information please
visit: <U>www.fibrogen.com</U>. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements: Astellas </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release includes forward-looking statements based on assumptions and beliefs in light of the information currently available to management and
subject to significant risks and uncertainties. Forward-looking statements include all statements other than statements of historical fact, including plans, strategies and expectations for the future. Statements made in the future tense, and words
such as &#147;anticipate,&#148; &#147;expect,&#148; &#147;project,&#148; &#147;continue,&#148; &#147;believe,&#148; &#147;plan,&#148; &#147;estimate,&#148; &#147;pro forma,&#148; &#147;intend,&#148; &#147;potential,&#148; &#147;target,&#148;
&#147;forecast,&#148; &#147;guidance,&#148; &#147;outlook,&#148; &#147;seek,&#148; &#147;assume,&#148; &#147;will,&#148; &#147;may,&#148; &#147;should,&#148; and similar expressions are intended to qualify as forward-looking statements.
Forward-looking statements are based on estimates and assumptions made by management that are believed to be reasonable, though they are inherently uncertain and difficult to predict. Investors and security holders are cautioned not to place undue
reliance on these forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Actual results may differ materially depending on a number of factors. This press release contains
information on pharmaceuticals (including compounds under development), but this information is not intended to make any representations or advertisements regarding the efficacy or effectiveness of these pharmaceuticals nor provide medical advice of
any kind. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements: FibroGen </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
release contains forward-looking statements, including statements regarding the tolerability of roxadustat, the potential ability of roxadustat to correct and maintain hemoglobin levels in CKD patients not on dialysis, and the potential for
continued safety or efficacy in our Phase 3 studies. Our actual results may differ materially from these early data and any forward-looking statements due to risks and uncertainties that are described in our Annual Report on Form 10-K and our
quarterly reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date
of this release and we undertake no obligation to update any forward-looking statement in this press release, except as required by law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Astellas
Contact: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TEL: 03-3244-3201
FAX: 03-5201-7473 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">http://www.astellas.com/en </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FibroGen
Contact: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leanne C. Price </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FibroGen, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>lprice@fibrogen.com</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.415.978.1200 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g212886img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g212886img1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 'P"K P$1  (1 0,1 ?_$ +T   (#  (#
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MU:<W/*5[I^.*@R7:-7EHO-DB*I7FKE\N1JR;N)B<>,8]%9VY4*FD4R@"<Y@
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MBZUV^-@LD^VO&">@+JZ@GW FIQCKE5XNW^1;B_=2R0WRN0,B0I4T'TTPQO\
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M%9R-3E7@-55CN"HJ.VQ@Y 0PDX66Y[AN=GY%_$.+QW$NXQRKVT[3-(^E0O\
M)@%B' J!2H4CZ<7W;[';[O@7R/(GABL9(V[C]Q51=1)_E"0H*$T)K0D85<PK
MB/R7Z$W_ "K+^*7,43N'A9>UNZQ)O]?G=0V!KKX6[)D^@IF[4"LR%KA8.;*Q
ME#MFDB<4%'*C5YV2%2+QHK=MSX%S*RMHO(]JVU[L(PX%R'MG%20RQR.$9EJ
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>_@LGX/H^8M/ZGTU[\5/ZSU5KKII]-735\-=66/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g212886img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g212886img2.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ - "W P$1  (1 0,1 ?_$ *X   $$ P$!
M       &!P@)! 4* P(! 0 " 04! 0             ! @,$!08("0<*$
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M^'U*&1GO);Q(J"PL.*YEMSMF:RR7>.$W4@_;G>6^AQ35OI;0S),Z[J38@<>
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M&B"<&H5LD''<HKODEW1=*I""(8YSM&SV]DX2GS7 'J[JX8#Z%>*?N-]X7/\
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M2HU9^3/B[(.G"39!OT=5XX<*IHMFC1KN1#N%'+A902D1133UF.<P@4I2"(Y
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1_%_=_9@[BX5]-?J0:?K7_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
